On March 11, 2026, FDA published a draft guidance that changes how flavored e-cigarette applications will be weighed: Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications, Considerations Related to Youth Risk. The Federal Register notice filed it under Docket No. FDA-2026-D-1817.
Before going further, one correction worth making plainly, because the opposite is widely repeated. This guidance does not create a tier system. There is no Tier 1 and no Tier 2. The document never uses the word "tier." It does not sort flavors into fixed categories with fixed requirement lists, and it does not mandate randomized controlled trials or blinded sensory panels for anyone. What it establishes is a graduated approach in which the evidence a specific applicant must produce scales with the youth risk that applicant's specific flavor can be shown to pose.
That difference is not pedantic. A tier system would tell you your obligations from your flavor name. A graduated approach tells you your obligations depend on evidence you have to go and generate. The second is harder to plan against, and it reaches further back into the supply chain.
What the Guidance Actually Establishes
The relevant section is titled "Graduated Risk-Proportionate Evaluation." The legal standard is unchanged: an ENDS product must be shown "appropriate for the protection of the public health" (APPH). What the guidance addresses is, in its own words, "the level of added adult benefit necessary to demonstrate APPH."
FDA's baseline position is that flavor raises youth risk across the board: "all flavoring in ENDS present a heightened risk to youth relative to tobacco-flavored ENDS." From there it graduates. FDA "will consider evidence regarding the level of youth risk of initiation and use a particular flavor poses when weighing risks and benefits," and will weigh applicant evidence "in proportion to the relative youth risk posed by the product's flavor characteristics."
For fruit and sweet flavors, the position is firm: "where high risk to youth of certain flavors is well-known and established, such as it currently is for flavors such as fruit and candy/dessert/other sweet, under this sliding scale the evidentiary burden remains high." FDA grounds that in survey data, noting that in 2024 the most commonly used ENDS flavor type among youth was fruit at 62.8%, followed by candy, dessert and other sweets at 33.3%, with menthol at 15.1% and tobacco at 8.5%.
At the other end, the language is conditional rather than categorical. Lower burden is available for "ENDS flavors for which there may be reliable scientific evidence demonstrating comparatively lower youth appeal and use, such as menthol, mint, and novel flavors (e.g., spice)." On coffee and spice specifically, FDA writes that "[s]ome flavors may be shown to have lower youth appeal, perhaps such as coffees, teas, or spices, such that they may pose a lower risk of appeal to youth and may be APPH if the added benefit they provide compared to tobacco-flavored products is relatively small."
Read the verbs. "May be shown." "May present." The lighter burden is not conferred by the flavor's name; it is earned by evidence. FDA closes the point directly: "it is the applicant's burden to show the product is APPH. If FDA does not have sufficient information regarding the product's potential risks and benefits, including the potential risks to youth, the applicant has not met its burden."
Studies FDA Suggests, Not Studies FDA Requires
Two study types get named in the guidance, and both are framed as options.
On randomized controlled trials, FDA says the evidence it considers "might include randomized controlled trials as well as observational studies examining real-world use patterns, perceptions, and behavioral outcomes." That is a description of admissible evidence, not a requirement.
On sensory work, FDA writes that "[s]ensory perception and consumer response studies, leveraging common and validated methods (e.g., blinded sensory panel assessments), may provide useful information regarding the relative appeal and sensory characteristics of ENDS flavor formulations without requiring product use," and that sample sizes "may be relatively modest." The optionality is explicit: "[w]here applicants choose to conduct such studies, final sample sizes should be justified with a power calculation." Where such studies are run, FDA recommends including "benchmark flavors that include tobacco, fruit, candy, and other common flavors to provide context for interpreting relative appeal."
FDA also invites applicants with other approaches "to request a meeting with FDA to discuss their study design plans," and says it "intends to consider input and emerging data regarding appropriate methodologies" and "may issue future guidance." This is an unsettled area, and the guidance says so.
Device Access Restrictions: Read the Guidance and the May Authorization Together
On age-gating technology, the guidance is cautious. An applicant "whose high youth appealing flavored ENDS purports to rely solely on DAR technology to address risk to youth carries an especially high burden to demonstrate adequate mitigation of such risk based on valid and reliable evidence from robust scientific investigations." FDA's stated current thinking is that such technologies "may be a component of a comprehensive youth prevention strategy" but "might not, standing alone, satisfy the especially high evidentiary burden" for high youth appealing flavors such as fruit and candy/dessert/other sweet.
Then FDA showed what clearing that burden looks like. On May 5, 2026, it authorized four Glas ENDS pods: Classic Menthol, Fresh Menthol, Gold, and Sapphire. FDA called this "the FDA's first authorization of non-tobacco and non-menthol ENDS products," and the deciding factor was precisely the technology the guidance warns about, backed by evidence:
The FDA's rigorous, scientific review of these products found that the applicant sufficiently demonstrated that Glas's device access restriction technology, combined with FDA-required marketing restrictions, is expected to effectively mitigate the ability of youth to use the product.
The technology requires government-issued ID verification, Bluetooth pairing with a smartphone so the device will not operate when separated from it, and random biometric check-ins. The applicant also showed that most adults aged 21 and over completed age verification successfully "while youth and young adults could not." CTP Acting Director Bret Koplow called device access restrictions "a potential game changer," and FDA stated that "[w]ith these orders, the FDA confirms the availability of an additional way for demonstrating that a non-tobacco flavored product meets the public health standard by using effective age-gating."
The lesson for planning is not that age-gating is a shortcut. It is that the guidance's high bar is a bar, not a wall, and it is cleared with evidence rather than assertion.
The Current Landscape: Flavored Authorizations Now Exist
FDA's list of authorized e-cigarettes holds 45 products across five manufacturers: Glas, JUUL Labs, Logic Technology Development, NJOY, and R.J. Reynolds Vapor Company. The overwhelming majority are tobacco or menthol. Two, the Glas Gold and Sapphire pods, are neither, and they are the first of their kind.
So the accurate statement is no longer that no flavored ENDS product has been authorized. Menthol-flavored products have carried authorizations for years, and FDA says so in the guidance itself: "FDA has issued marketing granted orders (MGOs) for menthol-flavored ENDS products where applicants demonstrated that marketing such products satisfied the APPH standard." As of May 2026, non-tobacco non-menthol products have authorizations too. The accurate statement is that the number remains very small relative to the market.
The denial side dwarfs it. FDA's first ENDS marketing denial orders covered about 55,000 flavored products from three applicants that lacked sufficient evidence of benefit to adult smokers to overcome youth risk. That figure is a single action, not a running total; FDA has since acted on more than 99% of the roughly 26 million deemed products for which applications were submitted, denying marketing for more than a million flavored ENDS products.
Enforcement against unauthorized product continues in parallel. A joint federal operation seized $76 million in illegal e-cigarettes, and a later HHS and CBP operation seized 4.7 million units with an estimated retail value of $86.5 million, the largest of its kind.
Meanwhile youth use is falling. FDA's 2025 National Youth Tobacco Survey findings put current e-cigarette use among high school students at 7.1%, down from 27.5% in 2019. The guidance does engage with declining trends rather than ignoring them: it notes that youth menthol ENDS use fell from 26.6% in 2022 to 15.1% in 2024, and treats that decline as part of why menthol applications may need to show a smaller incremental adult benefit.
What This Means for Nicotine Ingredient Documentation
The guidance sets no new ingredient-level requirements. It is about flavor risk assessment. But the evidence it contemplates creates demands that land upstream, and FDA's February 10, 2026 roundtable on ENDS premarket submissions spelled several of them out. Those materials carry FDA's disclaimer that they are not a formal dissemination of Agency policy, but as a statement of what reviewers keep finding missing, they are the most useful published artifact available.
Batch-to-Batch Consistency
FDA's roundtable materials tie nicotine consistency directly to abuse liability: if consumer use varies, exposure to harmful and potentially harmful constituents "may be higher than anticipated," and "[a]buse liability may be impacted, an increased quantity of nicotine may be more addictive." FDA also warns that inconsistency undermines the studies themselves: reviewers "won't know if the products used for abuse liability and other clinical or behavioral studies are representative" of what consumers actually get.
The corresponding ask is concrete. FDA's materials tell applicants to "[p]rovide target nicotine quantity specifications, upper and lower range limits, and acceptance criteria for the finished products" and to "[i]nclude in-process checks to ensure nicotine quantity is within specifications at each step."
That flows straight to the supplier. FDA's list of common quality system document problems includes Certificates of Analysis "missing: target specification with units, quantitative acceptance criteria with units, test data average, either standard deviation or minimum and maximum values." A CoA that reports a single number, or a pass/fail, is one of the named gaps.
Suppliers providing USP/EP grade nicotine with full batch-level Certificates of Analysis carrying those fields give their customers a defensible starting point. Suppliers who cannot provide lot-specific documentation force manufacturers to verify every shipment independently, adding cost and delay.
Flavor-Specific Constituent Characterization
Each flavor variant and nicotine strength is treated as a distinct product, which is why FDA's authorization lists enumerate individual SKUs rather than product families. A manufacturer with 15 SKUs is assembling 15 evidence packages, each requiring HPHC testing of the finished product's aerosol.
The nicotine ingredient's contribution to that profile must be documentable, including Tobacco Specific Nitrosamines, carbonyls, and any other constituents relevant to the formulation. When a formulation scientist calls asking for constituent-level data across multiple nicotine salt forms, that data needs to exist already.
Nicotine Identity, Source, and Enantiomeric Purity
FDA's product characterization materials specify the fields expected for nicotine: nicotine form (for example, salt), nicotine form name (for example, nicotine lactate), nicotine source (tobacco-derived or non-tobacco nicotine), enantiomeric purity for non-tobacco nicotine expressed as percent S or R, purity or grade such as USP, and a target quantity and range with units. Complex ingredients require each single chemical substance to be reported separately, with CAS number or IUPAC name and FDA UNII.
For suppliers offering nicotine alkaloid products including synthetic options, maintaining current enantiomeric purity records is an ongoing obligation, not a one-time test.
Tobacco Product Master Files
A TPMF lets an ingredient supplier submit proprietary formulation data directly to FDA without disclosing it to customers. The manufacturer references the TPMF in its PMTA and FDA reviews the confidential data during the application review. Where each flavor variant needs its own application, a current, comprehensive TPMF reduces documentation burden across every customer at once. A supplier without one forces each customer to document ingredient details independently, with less precision and no confidentiality protection.
What Changed Since This Guidance Published
Two things, and both matter for how you use the document.
The comment period closed on May 11, 2026. Suppliers no longer have an open window on this docket. If your documentation practices are affected by where the final guidance lands, the route now is watching for the final version and engaging through any future docket FDA opens, since the guidance itself says FDA "may issue future guidance, as appropriate, to clarify evidentiary expectations" on appeal methodology.
The Glas authorization landed on May 5, 2026, three weeks before comments closed, and it demonstrated a route to a non-tobacco non-menthol authorization that the draft guidance treats cautiously. Any read of this guidance that predates that authorization is incomplete.
One point of continuity is worth stating because it is easy to get wrong: this is draft guidance. It is non-binding and describes FDA's current thinking. It is not law, and nothing in it is enforceable as a requirement.
Lessons from the Pouch Pilot
FDA's nicotine pouch PMTA pilot, launched September 2025 and later closed to new products rather than canceled, is instructive here, though not for the reason usually given.
The pilot's innovation was procedural, not evidentiary. FDA described it as focusing review "on the most critical elements for this product category" and featuring "increased real-time communication between FDA and applicants." The first authorizations, six on! PLUS products in December 2025, came after scientific review completed in three months, which FDA called a record for a PMTA. FDA has since said it "has begun implementing efficiencies learned from the pilot to the review of other PMTAs."
The transferable lesson for ENDS applicants is about response speed, not documentation relief. When FDA asks a question mid-review, the clock is short. Suppliers who can produce a batch record the same week protect their customers' timelines; suppliers who cannot become the bottleneck.
One caution on cross-category reasoning: ZYN holds authorizations for ten flavors including Citrus, Coffee, and Cinnamon. That tells you nothing about how the same flavor would fare in an ENDS application. Nicotine pouches and ENDS are assessed on their own risk profiles, and authorization of a flavor in one category creates no precedent in the other.
Preparing Your Documentation Now
- Verify batch release data includes target concentrations, upper and lower range limits, acceptance criteria with units, and lot-specific impurity profiles, not a pass/fail line
- Confirm constituent characterization data covers TSNAs and relevant carbonyls for each nicotine form you supply
- Update or establish your TPMF with FDA, and confirm your letter of authorization process is current
- Document enantiomeric purity for any non-tobacco nicotine, expressed as percent S or R
- Compile stability data across the claimed shelf life, with measurements at the beginning, middle, and end of the proposed shelf life as FDA's roundtable materials recommend
The manufacturers who secure the next non-tobacco ENDS authorizations will be the ones whose whole evidence chain, from ingredient supplier through finished product testing, is audit-ready before the final guidance publishes. That readiness starts with the ingredient supply chain.
NicAlliance supplies USP/EP grade nicotine and nicotine salts with full documentation support, batch-level traceability, and TPMF capability. To check your current ingredient documentation against the standard this guidance implies, request a sample with full CoA documentation and compare it against your PMTA requirements.
Frequently Asked Questions
Does FDA's March 2026 flavored ENDS guidance create a tiered framework?
No. The draft guidance never uses the word "tier" and establishes no named categories with fixed requirement lists. Its section is titled "Graduated Risk-Proportionate Evaluation," and it describes a sliding scale in which FDA weighs an applicant's evidence "in proportion to the relative youth risk posed by the product's flavor characteristics." For flavors where high youth risk is well established, such as fruit and candy/dessert/other sweet, FDA says the evidentiary burden remains high. For flavors such as menthol, mint, and spice, a lower burden is available only where there is reliable scientific evidence of comparatively lower youth appeal. The lighter burden is earned by evidence, not conferred by the flavor's name.
Does the guidance require randomized controlled trials or blinded sensory panels?
No. Both are named as options, not mandates. FDA says the evidence it considers "might include randomized controlled trials as well as observational studies examining real-world use patterns, perceptions, and behavioral outcomes." On sensory work, FDA says blinded sensory panel assessments "may provide useful information" and refers to applicants who "choose to conduct such studies," recommending benchmark flavors including tobacco, fruit, and candy where they do. FDA also invites applicants with other rigorous approaches to request a meeting to discuss study design, and says it may issue future guidance clarifying methodology.
Have any flavored ENDS products been authorized by FDA?
Yes. Menthol-flavored ENDS have held marketing granted orders for years, a point FDA restates in the March 2026 draft guidance. On May 5, 2026, FDA authorized four Glas pods including Gold and Sapphire, which it called its first authorization of non-tobacco and non-menthol ENDS products; the deciding evidence was the applicant's device access restriction technology combined with FDA-required marketing restrictions. FDA's authorized e-cigarette list holds 45 products across five manufacturers. Authorizations remain very small in number relative to the market, and FDA has denied marketing for more than a million flavored ENDS products.
How does the guidance affect nicotine ingredient suppliers?
The guidance sets no ingredient-level requirements directly, but the evidence it contemplates creates upstream demands. FDA's February 2026 roundtable materials ask applicants for target nicotine quantity specifications with upper and lower range limits and acceptance criteria, and list Certificates of Analysis missing target specifications with units, quantitative acceptance criteria, test data averages, and standard deviation or minimum and maximum values as a recurring problem. Suppliers also face requests for constituent characterization across formulations, Tobacco Product Master File maintenance, and enantiomeric purity records for non-tobacco nicotine. Because each flavor variant and nicotine strength is a distinct product, the documentation burden multiplies across a manufacturer's line.